 Anti-HIV Agents
"Anti-HIV Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS.
| Descriptor ID |
D019380
|
| MeSH Number(s) |
D27.505.954.122.388.077.088
|
| Concept/Terms |
Anti-HIV Agents- Anti-HIV Agents
- Agents, Anti-HIV
- Anti HIV Agents
- Anti-AIDS Agents
- Agents, Anti-AIDS
- Anti AIDS Agents
- Anti-HIV Drugs
- Anti HIV Drugs
- Drugs, Anti-HIV
- AIDS Drugs
- Drugs, AIDS
- Anti-AIDS Drugs
- Anti AIDS Drugs
- Drugs, Anti-AIDS
|
Below are MeSH descriptors whose meaning is more general than "Anti-HIV Agents".
Below are MeSH descriptors whose meaning is more specific than "Anti-HIV Agents".
This graph shows the total number of publications written about "Anti-HIV Agents" by people in this website by year, and whether "Anti-HIV Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 1 | 2 | | 1998 | 5 | 4 | 9 | | 1999 | 5 | 3 | 8 | | 2000 | 4 | 0 | 4 | | 2001 | 5 | 1 | 6 | | 2002 | 3 | 1 | 4 | | 2003 | 2 | 2 | 4 | | 2004 | 9 | 1 | 10 | | 2005 | 8 | 4 | 12 | | 2006 | 5 | 2 | 7 | | 2007 | 5 | 2 | 7 | | 2008 | 9 | 2 | 11 | | 2009 | 10 | 3 | 13 | | 2010 | 11 | 2 | 13 | | 2011 | 10 | 8 | 18 | | 2012 | 18 | 2 | 20 | | 2013 | 14 | 3 | 17 | | 2014 | 22 | 6 | 28 | | 2015 | 15 | 5 | 20 | | 2016 | 30 | 11 | 41 | | 2017 | 27 | 9 | 36 | | 2018 | 23 | 6 | 29 | | 2019 | 19 | 5 | 24 | | 2020 | 28 | 6 | 34 | | 2021 | 38 | 5 | 43 | | 2022 | 37 | 0 | 37 | | 2023 | 33 | 2 | 35 | | 2024 | 18 | 9 | 27 | | 2025 | 20 | 2 | 22 |
To return to the timeline, click here.
Below are the most recent publications written about "Anti-HIV Agents" by people in Profiles.
-
Engel N, Sykes C, Schauer AP, Kashuba ADM, Anderson PL, Bushman LR, Cottrell ML. Interlaboratory comparison of a dried blood spot assay for antiretroviral adherence: implications for clinical application. J Antimicrob Chemother. 2025 Oct 03; 80(10):2727-2731.
-
Anderson PL, Coppinger C, Cottrell ML, Marzinke MA. Recommendations for Interpreting Intraerythrocytic Tenofovir Diphosphate and Emtricitabine Triphosphate for HIV-1 Preexposure Prophylaxis Adherence Assessment. J Acquir Immune Defic Syndr. 2025 Oct 01; 100(2):162-169.
-
Edwards KA, Long D, Jones KF, Durr AL, Farel CE, Liebschutz JM, Bair MJ, Agil D, Napravnik S, Browne L, Johnson B, Thomas T, Burkholder G, Clay OJ, Demonte W, Orris SM, Johnson MO, Merlin J. The Skills to Manage Pain Randomized Trial: Results of Antiretroviral Therapy Adherence, HIV Primary Care Retention, and Virologic Suppression Outcomes. J Acquir Immune Defic Syndr. 2025 Oct 01; 100(2):180-185.
-
Mugwanya KK, Saina M, Mugo NR, MaWhinney S, Morrow M, Schaafsma TT, Donnell D, Glidden DV, Ngure K, Brown CE, Rechkina EA, Chohan BH, Wu L, Hill E, Koome E, Akelo N, Mbaire S, Morrison SA, Kibatha M, Njeru I, Muriithi M, Coppinger C, Bushman L, Baeten JM, Anderson PL. Adherence thresholds for emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis against HIV acquisition in cisgender women: A randomized directly observed dosing study. PLoS Med. 2025 Sep; 22(9):e1004732.
-
Parikh UM, Kudrick LD, Levy L, Bosek E, Chohan BH, Mukui I, Masyuko S, Ndlovu N, Mahaka I, Mugurungi O, Ncube G, Hettema A, Matse SN, Mullick S, Wallis CL, Heaps AL, Penrose KJ, McCormick KD, Wiesner L, Anderson PL, Peterson JM, Celum C, Richardson BA, Castor D, Allen S, Torjesen K, Mellors JW. A cross-sectional study evaluating the frequency of HIV drug resistance mutations among individuals diagnosed with HIV-1 in tenofovir disoproxil fumarate-based pre-exposure prophylaxis rollout programmes in Kenya, Zimbabwe, Eswatini and South Africa. J Int AIDS Soc. 2025 Aug; 28(8):e70011.
-
Antwi S, Yang H, Enimil A, Martyn-Dickens C, Dompreh A, Sly-Moore E, Bosomtwe D, Amissah AK, Ojewale O, Asiedu P, Appiah AF, Opoku T, Sarfo AD, Kusi-Amponsah I, Bushman LR, Ellison L, Anderson PL, Kwara A. Tenofovir diphosphate concentrations in dried blood spots predict future HIV suppression but not virologic failure in adolescents with HIV. AIDS. 2025 Sep 01; 39(11):1668-1671.
-
Mainella VA, Branchford B, Nemkov T, Hosford S, Coyle RP, Johnson B, Choi YJ, Williams M, Zheng JH, Bushman L, Kiser JJ, Anderson PL, Brooks KM. Cellular pharmacology of tenofovir alafenamide and emtricitabine in neutrophils and platelets in people with and without HIV. J Antimicrob Chemother. 2025 May 02; 80(5):1224-1232.
-
Meyers K, Lane B, Zucker J, Wu Y, Carnevale C, Burnside H, Rowan S, Mayes E, Narcisse-Cempini G, Gold MA, Saldana L, Golub SA. A case study of the co-creation of the PrEP-SIC: a roadmap to support introduction of pre-exposure prophylaxis into new settings. BMC Health Serv Res. 2025 May 01; 25(1):631.
-
Hiransuthikul A, Thammajaruk N, Kerr S, Janamnuaysook R, Nonenoy S, Hongchookiat P, Trichavaroj R, Tawon Y, Boonruang J, Teeratakulpisarn N, Cressey TR, Anderson PL, Phanuphak N. No significant drug-drug interaction between oral TAF-based PrEP and feminizing hormone therapy among transgender women in Thailand: the iFACT-3 study. J Int AIDS Soc. 2025 May; 28(5):e26502.
-
Mutale W, Graybill LA, Saidi F, Phanga T, Amico KR, Freeborn K, Rosenberg NE, Hill LM, Hamoonga T, Richardson BD, Mollan KR, Chi BH. Evaluation of a combination adherence strategy to support HIV antiretroviral therapy for pregnancy and breastfeeding in Malawi: A pilot randomized clinical trial. PLoS One. 2025; 20(4):e0319735.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|